March 18, 2024 4:54pm
A scorecard of earnings releases of covered companies -
The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status".
26 of 35 covered released to date
COMPANY |
SYMBOL |
NET INCOME |
Q4/23 LOSS & LPS |
FY/23 LOSS or Net Income & LPS |
CASH POSITION | RUNWAY |
---|---|---|---|---|---|---|
Blueprint Medicine |
BPMC |
-$110.9 M -$1.82 pre-share |
-$570 M -$8.37 per share |
$767.2 M | 2026 | |
Agenus
|
AGEN
|
-$48.5 M -$0.13 per share |
-$257.4 M -$0.69 per share |
$76.1 M +$25 M (BMS) Potential $100-$200 M |
2025 | |
Alnylam Pharmaceuticals |
ALNY
|
-$96.6 M -$1.10 per share |
-$202.618 M -$3.52 per share |
$2.44 B |
2027 |
|
Prime Medicine |
PRME |
Hiding Them |
-$198. 1 M -$2.18 per share |
$138.2 M Raised 2/24 $161 M |
2026 | |
Adverum Biotechnologies |
ADVM
|
-$23.7 M -$0.33 pre share |
-$32.7 M -$0.33 per share |
$96.5 M Offering 2/24/23 $127.5 M |
Q4/25 | |
Compass Therapeutics
|
CMPX |
|
||||
AxoGen |
AXGN
|
-$3.9 M -$0.09 per share |
-$21.7 M -$0.57 per share |
$37 M |
2026 Revenue projection $177-$181 M in 2024 |
|
Bellicum Pharmaceuticals |
BLCM
|
|
|
|||
Beam Therapeutics |
BEAM |
Q4/23 +$142.8 M +$177 per share |
|
-$132.5 M -$1.72 per share |
$1.2 B | 2027 |
BioLife Solutions |
BLFS
|
|
-$13.38 M -$0.30 per share |
-$66.42 M -$1.52 per share |
$52.3 M | 2026 |
Harvard Apparatus RT |
HRGN |
|
||||
bluebird bio
|
BLUE
|
|
||||
Brainstorm Cell Therapeutics
|
BCLI |
|
||||
Caribou Biosciences |
CRBU |
-$34.5 M -$0.39 per share |
-$102.1 M -$1.38 per share |
$372.4 M | Q1/26 | |
Cellectis SA |
CLLS
|
|
|
|||
CRISPR Therapeutics |
CRSP
|
+$89.3 M +$1.10 per share |
|
-$136,650 M -$1.95 per share |
$1,695,7 M | 2027 |
Editas Medicine |
EDIT
|
|
-$18.9 M -$0.23 per share |
-$153.2 M -$2.02 per share |
$427 M |
2026 |
Fate Therapeutics |
FATE
|
-$44.1 M -$0.45 per share |
-$169.9 M -$1.64 |
$316.2 M | early 2025 | |
Graphite Bio |
GRPH |
|
|
|||
Homology Medicine |
FIXX |
|
||||
Intellia Therapeutics |
NTLA
|
-$132.2 M -$1.46 per share |
-$481.19 -$5.42 per share |
$1 B | mid 2026 | |
Precigen |
PGEN
|
|
||||
Ionis Pharmaceuticals |
IONS
|
|
|
|
||
Mesoblast |
MESO
|
Hiding them |
-$32,5 M -$3.82 per share |
$77.6 M <-$6.9 M in financing cost> |
2025 | |
MiMedx Group |
MDXG
|
+$53 M +$0.32 per share
|
FY23 'Net Income +$58.22 +0.37 |
$82 M |
2025
|
|
Verve Therapeutics |
VERV |
-$48.4 M -$0.69 per share |
-$200.1 M -$3.12 per share |
$624 M | 2026 | |
Regenxbio
|
RGNX
|
|
-$62.9 M -$1.43 per share |
-$263.5 M -$6.02 per share |
$314 M | Q2/2025 |
Sage Therapeutics |
SAGE
|
-$32.7 M -$0.55 per share |
-$541.5 M -$9.05 per share |
$753 M |
2026 |
|
Sangamo Biosciences |
SGMO
|
-$60.3 M -$0.34 per share |
-$257.8 M -$1.48 per share |
$81 M | Q3/24 | |
Solid Biosciences |
SLDB
|
-$20.3 M Hiding per share |
-$96 M -$4.83 |
$123.6 M $108.9 M raised 1/24 |
2026 | |
Ultragenyx Pharmaceuticals |
RARE |
-$123.19 M -$1.52 per share |
-$606, 639 M -$8.25 |
$777 M | 2025 | |
uniQure N.V.
|
QURE
|
|
Hiding them |
-$308.5 M -$6.47 per share |
$617.9 M | 2025 |
Generation Bio |
GBIO |
-$35.2 M -$o,53 |
-$126.6 M -$1.96 |
$264.4 M | 2H/2027 | |
Vericel
|
VCEL
|
+$13 M +$0.26 per share |
|
FY23 Net Loss -$3.2 M -$0.07 per share |
$152.6 M |
2027 |
Voyager Therapeutics |
VYGR
|
+$56.4 M +$1.28 per share |
|
FY23 Net Income +$32.3 M +$3.08 |
Close of '23 = $230.9 M Current: $431 M |
2027 |